Peter Wipfler

920 total citations
56 papers, 658 citations indexed

About

Peter Wipfler is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Peter Wipfler has authored 56 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 19 papers in Neurology and 18 papers in Oncology. Recurrent topics in Peter Wipfler's work include Multiple Sclerosis Research Studies (35 papers), Peripheral Neuropathies and Disorders (15 papers) and Polyomavirus and related diseases (11 papers). Peter Wipfler is often cited by papers focused on Multiple Sclerosis Research Studies (35 papers), Peripheral Neuropathies and Disorders (15 papers) and Polyomavirus and related diseases (11 papers). Peter Wipfler collaborates with scholars based in Austria, Germany and United States. Peter Wipfler's co-authors include Georg Pilz, Andrea Harrer, Eugen Trinka, Jörg Kraus, Elisabeth Haschke‐Becher, Katrin Oppermann, Johann Sellner, Wolfgang Hitzl, Ferdinand Otto and Tobias Moser and has published in prestigious journals such as PLoS ONE, Neurology and Journal of Virology.

In The Last Decade

Peter Wipfler

50 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Wipfler Austria 17 362 178 168 166 142 56 658
Alexander Winkelmann Germany 15 585 1.6× 239 1.3× 164 1.0× 156 0.9× 193 1.4× 43 828
Paolo Ripellino Switzerland 14 282 0.8× 154 0.9× 272 1.6× 147 0.9× 88 0.6× 44 786
Philipp Schwenkenbecher Germany 21 400 1.1× 307 1.7× 117 0.7× 125 0.8× 106 0.7× 56 902
Jasem Al–Hashel Kuwait 20 587 1.6× 214 1.2× 132 0.8× 122 0.7× 69 0.5× 67 872
Augusto Miravalle United States 10 412 1.1× 155 0.9× 132 0.8× 208 1.3× 41 0.3× 28 629
Ryan Ramanujam Sweden 14 472 1.3× 185 1.0× 180 1.1× 141 0.8× 38 0.3× 27 804
Karen O’Connell Ireland 13 231 0.6× 106 0.6× 136 0.8× 53 0.3× 140 1.0× 29 683
Louise Wienholt Australia 12 249 0.7× 370 2.1× 185 1.1× 80 0.5× 109 0.8× 36 901
Markus C. Kowarik Germany 15 483 1.3× 289 1.6× 357 2.1× 141 0.8× 70 0.5× 48 977
Julia O’Mahony Canada 16 589 1.6× 325 1.8× 149 0.9× 102 0.6× 37 0.3× 43 840

Countries citing papers authored by Peter Wipfler

Since Specialization
Citations

This map shows the geographic impact of Peter Wipfler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wipfler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wipfler more than expected).

Fields of papers citing papers by Peter Wipfler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wipfler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wipfler. The network helps show where Peter Wipfler may publish in the future.

Co-authorship network of co-authors of Peter Wipfler

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Wipfler. A scholar is included among the top collaborators of Peter Wipfler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Wipfler. Peter Wipfler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Messner, Mark, Janne Cadamuro, Hannes Oberkofler, et al.. (2025). Long-term impact of oral cladribine on humoral immunity in multiple sclerosis. Therapeutic Advances in Neurological Disorders. 18. 4243638363–4243638363.
2.
Harrer, Andrea, Barbara A. Slade, Hannes Oberkofler, et al.. (2025). Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity. Neurology and Therapy. 14(6). 2583–2604.
3.
4.
Otto, Ferdinand, Lara Bieler, Tobias Moser, et al.. (2024). Beyond T cell toxicity – Intrathecal chemokine CXCL13 indicating B cell involvement in immune‐related adverse events following checkpoint inhibition: A two‐case series and literature review. European Journal of Neurology. 31(7). e16279–e16279. 7 indexed citations
5.
6.
Pilz, Georg, Peter Wipfler, Andrea Harrer, et al.. (2023). Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders—A Pilot Study. International Journal of Molecular Sciences. 24(7). 6552–6552. 5 indexed citations
7.
Hitzl, Wolfgang, Arabella Buchmann, Michael Khalil, et al.. (2023). Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences. 24(4). 4067–4067. 13 indexed citations
8.
Bsteh, Gabriel, Nik Krajnc, Franziska Di Pauli, et al.. (2022). Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study. European Journal of Neurology. 29(10). 3050–3060. 20 indexed citations
9.
Bsteh, Gabriel, Harald Hegen, Franziska Di Pauli, et al.. (2022). Impact of vaccination on COVID‐19 outcome in multiple sclerosis. European Journal of Neurology. 29(11). 3329–3336. 12 indexed citations
10.
Bsteh, Gabriel, Harald Hegen, Fritz Leutmezer, et al.. (2021). Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. Multiple Sclerosis Journal. 27(14). 2209–2218. 22 indexed citations
11.
Moser, Tobias, Ciara K. O’Sullivan, Georg Pilz, et al.. (2021). Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy. Biomedicines. 9(11). 1584–1584. 10 indexed citations
12.
Pilz, Georg, Peter Wipfler, Jörg Kraus, et al.. (2020). Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction. Fluids and Barriers of the CNS. 17(1). 7–7. 21 indexed citations
13.
Moser, Tobias, et al.. (2020). Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. Multiple Sclerosis and Related Disorders. 48. 102727–102727. 5 indexed citations
14.
Pilz, Georg, Peter Wipfler, Ferdinand Otto, et al.. (2019). Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study. Journal of Neuroinflammation. 16(1). 13–13. 12 indexed citations
15.
Harrer, Andrea, Georg Pilz, Katrin Oppermann, et al.. (2017). From natalizumab to fingolimod in eight weeks — Immunological, clinical, and radiological data in quest of the optimal switch. Clinical Immunology. 176. 87–93. 4 indexed citations
16.
Wipfler, Peter, Nicky Dunn, Omid Beiki, Eugen Trinka, & Anna Fogdell‐Hahn. (2017). The Viral Hypothesis of Mesial Temporal Lobe Epilepsy – Is Human Herpes Virus-6 the Missing Link? A systematic review and meta-analysis. Seizure. 54. 33–40. 32 indexed citations
17.
18.
Harrer, Andrea, Georg Pilz, Katrin Oppermann, et al.. (2012). Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis. PLoS ONE. 7(2). e31784–e31784. 17 indexed citations
19.
Kunz, Alexander, Jörg Kraus, Peter Young, et al.. (2012). Biomarkers of Inflammation and Endothelial Dysfunction in Stroke with and without Sleep Apnea. Cerebrovascular Diseases. 33(5). 453–460. 25 indexed citations
20.
Pilz, Georg, Peter Wipfler, G. Ladurner, & Jörg Kraus. (2008). Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today. 13(23-24). 1013–1025. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Winkelmann Breakdown of academic impact, for papers by Paolo Ripellino Breakdown of academic impact, for papers by Philipp Schwenkenbecher Breakdown of academic impact, for papers by Jasem Al–Hashel Breakdown of academic impact, for papers by Augusto Miravalle Breakdown of academic impact, for papers by Ryan Ramanujam Breakdown of academic impact, for papers by Karen O’Connell Breakdown of academic impact, for papers by Louise Wienholt Breakdown of academic impact, for papers by Markus C. Kowarik Breakdown of academic impact, for papers by Julia O’Mahony
Rankless by CCL
2026